Dutch biotech company SkylineDx reported on Monday the receipt of EUR20m in capital to proceed with its skin cancer (melanoma) diagnostic test from Benelux' largest biotech investor Aat van Herk.
This melanoma test was reportedly discovered by a renowned US hospital and is further being optimised and developed by SkylineDx.
Based on the unique combination of genetic information from the primary melanoma cells and other patient and tumour characteristics, the company's test is able to accurately predict the risk of having metastases present in the lymph nodes without having to undergo a surgery to remove part of the lymph nodes. Up to 80% of these biopsies could be safely avoided as they turn out to have no sign of cancerous cells.
The company added that it has appointed Professor Alexander Eggermont as it medical advisor. He is the general director of cancer center Gustave Roussy in Paris and a highly respected expert physician in the melanoma space.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer